JP2018512442A - 超微細脂質構造体の作製のためのワンステップ法 - Google Patents
超微細脂質構造体の作製のためのワンステップ法 Download PDFInfo
- Publication number
- JP2018512442A JP2018512442A JP2017554519A JP2017554519A JP2018512442A JP 2018512442 A JP2018512442 A JP 2018512442A JP 2017554519 A JP2017554519 A JP 2017554519A JP 2017554519 A JP2017554519 A JP 2017554519A JP 2018512442 A JP2018512442 A JP 2018512442A
- Authority
- JP
- Japan
- Prior art keywords
- usls
- lipid
- water
- passenger
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title description 14
- 125000003473 lipid group Chemical group 0.000 title 1
- 150000002632 lipids Chemical group 0.000 claims abstract description 70
- 150000001875 compounds Chemical class 0.000 claims abstract description 54
- 239000003960 organic solvent Substances 0.000 claims abstract description 32
- 235000013305 food Nutrition 0.000 claims abstract description 13
- 238000007865 diluting Methods 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 73
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 62
- 150000003904 phospholipids Chemical class 0.000 claims description 42
- 235000000346 sugar Nutrition 0.000 claims description 29
- 239000000243 solution Substances 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 19
- 150000008163 sugars Chemical class 0.000 claims description 18
- -1 lipid compounds Chemical class 0.000 claims description 16
- 239000011550 stock solution Substances 0.000 claims description 15
- 235000019640 taste Nutrition 0.000 claims description 15
- 238000010790 dilution Methods 0.000 claims description 13
- 239000012895 dilution Substances 0.000 claims description 13
- 238000003860 storage Methods 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 239000003761 preservation solution Substances 0.000 claims description 6
- 230000000873 masking effect Effects 0.000 claims description 5
- 235000015097 nutrients Nutrition 0.000 claims description 5
- 241000196324 Embryophyta Species 0.000 claims description 4
- 235000015218 chewing gum Nutrition 0.000 claims description 4
- 235000019219 chocolate Nutrition 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- 239000002324 mouth wash Substances 0.000 claims description 4
- 239000003791 organic solvent mixture Substances 0.000 claims description 4
- YEYKMVJDLWJFOA-UHFFFAOYSA-N 2-propoxyethanol Chemical compound CCCOCCO YEYKMVJDLWJFOA-UHFFFAOYSA-N 0.000 claims description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 3
- 229940112822 chewing gum Drugs 0.000 claims description 3
- 235000020778 linoleic acid Nutrition 0.000 claims description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 3
- 229960004488 linolenic acid Drugs 0.000 claims description 3
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- 239000008347 soybean phospholipid Substances 0.000 claims description 3
- 235000012041 food component Nutrition 0.000 claims description 2
- 239000005417 food ingredient Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000002245 particle Substances 0.000 abstract description 46
- 230000008569 process Effects 0.000 abstract description 9
- 235000013361 beverage Nutrition 0.000 abstract description 5
- 239000002537 cosmetic Substances 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 description 69
- 239000000047 product Substances 0.000 description 42
- 238000009472 formulation Methods 0.000 description 41
- 238000002296 dynamic light scattering Methods 0.000 description 30
- 239000002904 solvent Substances 0.000 description 25
- 239000012153 distilled water Substances 0.000 description 24
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 21
- 239000000126 substance Substances 0.000 description 21
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 20
- 239000002502 liposome Substances 0.000 description 20
- 235000010469 Glycine max Nutrition 0.000 description 18
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 16
- 230000018044 dehydration Effects 0.000 description 14
- 238000006297 dehydration reaction Methods 0.000 description 14
- 239000000463 material Substances 0.000 description 12
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 235000013343 vitamin Nutrition 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 238000007710 freezing Methods 0.000 description 7
- 230000008014 freezing Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 230000009919 sequestration Effects 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 5
- 229930003779 Vitamin B12 Natural products 0.000 description 5
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 description 5
- 239000001755 magnesium gluconate Substances 0.000 description 5
- 229960003035 magnesium gluconate Drugs 0.000 description 5
- 235000015778 magnesium gluconate Nutrition 0.000 description 5
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 235000019163 vitamin B12 Nutrition 0.000 description 5
- 239000011715 vitamin B12 Substances 0.000 description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000000149 argon plasma sintering Methods 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 239000013020 final formulation Substances 0.000 description 4
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 description 4
- 239000000626 magnesium lactate Substances 0.000 description 4
- 229960004658 magnesium lactate Drugs 0.000 description 4
- 235000015229 magnesium lactate Nutrition 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 3
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- NZDXSXLYLMHYJA-UHFFFAOYSA-M 4-[(1,3-dimethylimidazol-1-ium-2-yl)diazenyl]-n,n-dimethylaniline;chloride Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1N=NC1=[N+](C)C=CN1C NZDXSXLYLMHYJA-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 229940126575 aminoglycoside Drugs 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 229940030275 epigallocatechin gallate Drugs 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000011882 ultra-fine particle Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- AWBXTNNIECFIHT-XZQQZIICSA-N 2-[(1r,2r,3s,4r,5r,6s)-3-(diaminomethylideneamino)-4-[(2r,3r,4r,5s)-3-[(2s,3s,4s,5r,6s)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;2-[(1r,2r,3s,4r,5r,6s)-3-( Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O AWBXTNNIECFIHT-XZQQZIICSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000021310 complex sugar Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000000959 cryoprotective effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000001632 homeopathic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000006207 intravenous dosage form Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000013554 lipid monolayer Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 125000000647 trehalose group Chemical group 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/30—Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/32—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds
- A23G1/36—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds characterised by the fats used
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/84—Flavour masking or reducing agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/04—Making microcapsules or microballoons by physical processes, e.g. drying, spraying
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/26—Optical properties
- A61K2800/262—Transparent; Translucent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Birds (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oral & Maxillofacial Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Confectionery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明での使用に好ましい脂質には、リン脂質、例えばリン脂質のアシル鎖の構成成分としてリノレン酸及びリノール酸を含むホスファチジルコリンを主に含む混合天然リン脂質が含まれる。これらは、当該分野で公知の大豆、菜種、ヒマワリ、家禽の卵黄、魚の卵及び牛乳中に見出され、これらのソースから周知の方法に従って精製することができる。
適切な有機溶媒は、一般に、脂質及び意図されるパッセンジャー化合物の両方が十分に可溶性であるハイドロ有機溶剤混合物を生成するものである。一般に、最も好ましい溶剤は、水と低分子量の有機溶剤との混合物である。エタノール、プロパノール、ブタノール、イソプロパノール、クロロホルム、アセトン、塩化メチレン又はプロピルグリコールなどの低分子量有機溶剤、又はそれらの混合物が適している。さらに、溶剤は、USLSの特定の意図された用途に適切であり、水と十分に混合可能でなければならない。USLSを例えば静脈内混入のような生体内で使用する場合、その使用において溶剤は十分に非毒性でなければならず、一般に生体適合性でなければならず、血液などの生物学的液体と容易に混合可能でなければならない。したがって、このタイプの使用にはエタノール(試薬グレード)が最も好ましい。好ましくは、全ての溶剤は試薬グレードである。
本発明による方法で使用される水は、任意の供給源からの飲料水であることができるが、好ましくは、蒸留水又は脱イオン水などの精製水である。滅菌水を使用することができる。
USLSは、脂質のハイドロ有機溶剤と隔離されるパッセンジャー化合物を作製することによって調製される。適切なハイドロ有機溶剤系は、約0.1〜約20%の水(v/v)、約0.5〜約15%の水(v/v)、約1〜約10%の水(v/v)、最も好ましくは約5〜約10%の水(v/v)を含む。例示的な量の水は、約1%水(v/v)、約5%水(v/v)、約12%水(v/v)及び約15%水(v/v)を含むが、これに限定されず、最も好ましくは約10%(v/v)の水を含む。残りの溶剤(100%を構成する)は、エタノールなどの1つ以上の有機溶剤である。最も好ましい溶剤系は、10%の水及び90%の試薬級エタノールである。本発明の方法に従って使用される水は、好ましくは精製、蒸留又は脱イオン水であり、滅菌水であることができる。
本発明の構造体における隔離に適した材料には、最終的な超微細脂質構造体を形成するために使用されるハイドロ有機溶剤に溶解又は懸濁できる任意の材料が含まれる。したがって、USLS中の隔離のためのパッセンジャー化合物は、内部(水性)コア中又は外部脂質殻の不可欠な成分としてUSLSにおいて物理的に隔離され得る任意の物質であり得、親油性、親水性又は両親媒性であり得る。
必要に応じて、例えば、トレハロース、スクロース、マルトース及びフルクトースなどの糖が挙げられるが、これらに限定されない糖を含む、光学的に透明な保存溶液に追加の成分を添加することができる。1つの好ましい実施形態では、特に後の段階で最終生成物を脱水することが望ましい場合には、糖が溶液に添加される。さらに、USLSを製造した後、それらが含有される溶液をこれらの糖を含むように変更してもよく、又は製品に外的糖のみが必要な場合には糖をUSLSに添加してもよい。
本明細書に記載される保存溶液は、水と約1:5〜約1:100の比で1段階で希釈される(すなわち、1部の溶液対約4部の水、1部の溶液対約99部の水)。希釈のための例示的な比としては、1:5、1:10、1:25、1:50、1:75及び1:100が挙げられるが、これらに限定されない。好ましい希釈率は、1:10(1部の溶液対9部の水)である。この希釈工程において、USLS(最終生成物)が形成される。
本発明のUSLSは、液体、固体及び蒸気を含む、様々な食品、化粧品及び医薬品に使用することができる。製品は、局所投与、経口摂取、静脈注射又は他の注射経路、吸入又は他の投与方法及び使用のために使用できる、ゲル、ローション、クリーム、エマルジョン、懸濁液、凍結乾燥製品、噴霧乾燥製品、粉末及び溶剤などの形態で有用であると考えられる。製品は、固体又は液体の食品、及び、摂取又は投与のための補助組成物に組み込むことができる。あるいは、USLSは、使用前にユーザによって追加される別個の容器内に医薬品又は食品を提供することができる。
1.例えば、飲料、チョコレート及び他の菓子、チューインガム、加工食品などの食品及び食料製品。
2.例えば、消毒スプレー、固体経口投与剤形、液体経口投与剤形、直腸又は膣座薬、鼻スプレー、吸入又はネブライザー製品、経皮パッチ、経粘膜投与剤形、希釈用の静脈内投与形、直接注射用の静脈内形、皮下及び筋肉内デポー形、及びヒト又は獣医学における使用のための薬品、医薬品及び応急処置製品。
3.例えば、水分補給製品、エネルギー飲料、ビタミン、ハーブ、ホメオパシー化合物などのサプリメント。
4.例えば、うがい薬、口内洗浄剤、ゲル、石鹸、チューインガム、溶解性ストリップ、喉スプレー、点眼剤、スキンケア製品、クリーム、ローションなどの口腔ケア製品を含むパーソナルケア製品。
5.例えば、植物及び動物の疾病の治療のための、及び、成長促進又は保護化合物の送達のための、液体、乾燥又は固体製剤を含む農産物。
以下の実施例は、一貫した結果及び狭いサイズ範囲で、平均直径100nm未満のUSLSを形成する、1つのプロセス工程で、パッセンジャー分子を封鎖する非常に小さい脂質小胞を生成することができることを示す。
本発明は、記載される特定のプロセス、組成物、又は方法論に限定されず、これらは変更されてもよい。したがって、以下の実施例は、本発明を説明するためのものであり、限定的ではなく例示的なものである。
ホスファチジルコリン及びリゾホスファチジルコリン(混合物中の総リン脂質の重量パーセントで約3%w/wのリゾホスファチジルコリン)を含む天然大豆リン脂質(188mg)の混合物を、90%のエタノールと10%の蒸留水(v/v)とからなるハイドロ有機溶剤の10mlに溶解した。得られた製剤は光学的に透明であった。
ホスファチジルコリン及びリゾホスファチジルコリン(混合物中の総リン脂質の重量パーセントで約3%w/wのリゾホスファチジルコリン)を含む天然大豆リン脂質(188mg)の混合物を、90%のエタノールと10%の蒸留水(v/v)とからなるハイドロ有機溶剤に溶解した。次いで、エピガロカテキンガレート(EGCG;1,500mg)をリン脂質、エタノール及び水からなるこの製剤に溶解した。得られた製剤は光学的に透明であり、ルビー色の赤色であり、室温で安定であった。
エピガロカテキンガレート(EGCG;1,500mg)を90%のエタノール及び10%の蒸留水(v/v)からなる10mlのハイドロ有機溶剤に溶解した。ホスファチジルコリンとリゾホスファチジルコリン(混合物中の総リン脂質の重量パーセントで約3%w/wのリゾホスファチジルコリン)とを含む天然大豆リン脂質(188mg)の混合物を、EGCG、エタノール及び水からなるこの製剤に溶解した。得られた脂質調製物は、光学的に透明であり、ルビー色の赤色であり、室温で安定であった。
ホスファチジルコリン及びリゾホスファチジルコリン(混合物中の総リン脂質の重量パーセントで約3%w/wのリゾホスファチジルコリン)を含む天然大豆リン脂質(188mg)の混合物を、90%のエタノール及び10%の蒸留水(v/v)からなるハイドロ有機溶剤に溶解した。グルコン酸マグネシウム(5.2g)を蒸留水150mlに溶解した。リン酸大豆を含むハイドロ有機溶剤を、このグルコン酸マグネシウム溶液に直接添加した。得られた製剤は、光学的に透明で、室温で安定であった。
ホスファチジルコリン及びリゾホスファチジルコリン(混合物中の総リン脂質の重量パーセントで約3%w/wのリゾホスファチジルコリン)を含む天然大豆リン脂質(188mg)の混合物を、90%のエタノール及び10%の蒸留水(v/v)からなるハイドロ有機溶剤に溶解した。塩化マグネシウム(5.2g)を蒸留水150mlに溶解した。大豆リン脂質を含むハイドロ有機溶剤を、この塩化マグネシウム溶液に直接加えた。得られた調製物は、光学的に透明で、室温で安定であった。
ホスファチジルコリン及びリゾホスファチジルコリン(混合物中の総リン脂質の重量パーセントで約3%w/wのリゾホスファチジルコリン)を含む天然大豆リン脂質(188mg)の混合物を、90%のエタノール及び10%の蒸留水(v/v)からなるハイドロ有機溶剤に溶解した。乳酸マグネシウム(5.2g)を150mlの蒸留水に溶解した。大豆リン脂質を含有するハイドロ有機溶剤を乳酸マグネシウムの溶液に直接加えた。得られた製剤は、光学的に透明で、室温で安定であった。
ホスファチジルコリン及びリゾホスファチジルコリン(混合物中の総リン脂質の重量パーセントで約3%w/wのリゾホスファチジルコリン)を含む天然大豆リン脂質(3,750mg)の混合物を、90%のエタノール及び10%の蒸留水(v/v)からなるハイドロ有機溶剤に溶解した。塩化ナトリウム(73g)、塩化カリウム(265g)、クエン酸ナトリウム(50.5g)を4800mlの蒸留水に溶解した。大豆リン脂質を含有するハイドロ有機溶剤を、この電解質塩の溶液に直接添加した。得られた製剤は、光学的に透明で、室温で安定であった。
ホスファチジルコリン及びリゾホスファチジルコリン(混合物中の総リン脂質の重量パーセントで約3%w/wのリゾホスファチジルコリン)を含む天然大豆リン脂質(188mg)の混合物を、90%のエタノール及び10%の蒸留水(v/v)からなるハイドロ有機溶剤に溶解した。ビタミンB12(500mg)を150mlの蒸留水に溶解した。ビタミンB12のこの溶液に、大豆リン脂質を含むハイドロ有機溶液を直接添加した。得られた製剤は、光学的に透明で、室温で安定であった。
10匹の200gの雄ラットの群に、実施例3(2.1ml;100mg/kg体重)のように調製したUSLSの形態で、又はUSLSを含まないEGCGの同一製剤として経口胃管栄養法によりEGCGを投与した。投与後、5分、10分、30分、60分、120分、及び480分に血液試料を採取した。USLS隔離されたEGCG(曲線A)及びUSLGなしのEGCG(曲線B)について示された時点+/− SEMでのEGCGの平均濃度を示す図4を参照されたい。経口投与後5分以内に、USLSで隔離された化合物は、600ng/mlの血漿濃度を生じ、投与後10分で605ng/mlのピーク血漿濃度を生じた。USLS中で隔離されずに投与されたEGCGは、投与後5分でわずか150ng/mlのピーク血漿濃度を生じた。したがって、USLS隔離された製品は、USLSなしのものよりも4倍高いピーク血漿濃度を示した。
1.ファウンテン(Fountain)の米国特許公開第2014−0271782号
2.ファウンテン(Fountain)の米国特許公開第2015−0342226号
3.ファウンテン(Fountain)の米国特許第4,588,578号
4.ファウンテン(Fountain)の米国特許第5,269,979号
5.ファウンテン(Fountain)の米国特許第5,879,703号
6.ヤノフ(Janoff)の米国特許第5,922,350号
7.ファウンテン(Fountain)の米国特許第8,545,874号
8.ファウンテン(Fountain)の米国特許第8,545,875号
9.ファウンテン(Fountain)の米国特許第8,597,678号
Claims (30)
- 超微細脂質構造体(USLS)を作製する方法であって、
(a)約0.1%〜約20%の水と約80%〜約99.9%の1種以上の水混和性有機溶媒とを含むハイドロ有機溶剤混合物と;
(b)約50mg/ml〜約250mg/mlの1種以上の脂質化合物と;
(c)1つ以上のパッセンジャー化合物と;
を含有する光学的に透明な保存溶液を、水による約1:5〜約1:200の希釈比で希釈する単一工程を含む方法。 - 前記光学的に透明な保存溶液は、1つ以上の糖をさらに含む、請求項1に記載の方法。
- 前記USLSを脱水することをさらに含む、請求項1に記載の方法。
- 前記USLSを再水和することをさらに含む、請求項3に記載の方法。
- 前記ハイドロ有機溶剤混合物は、約10%の水を含む、請求項1に記載の方法。
- 前記水混和性有機溶媒は、エタノール、プロパノール、ブタノール、イソプロパノール、クロロホルム、アセトン、塩化メチレン及びプロピルグリコールからなる群から選択される、請求項1に記載の方法。
- 前記水混和性有機溶媒は、エタノールである、請求項6に記載の方法。
- 前記光学的に透明な保存溶液は、約20mg/mlの脂質化合物を含む、請求項1に記載の方法。
- 前記1つ以上の脂質化合物は、リン脂質のアシル鎖として、リノレン酸及びリノール酸を含む植物源由来の混合リン脂質である、請求項1に記載の方法。
- 前記1つ以上の脂質化合物は、大豆リン脂質を含む、請求項9に記載の方法。
- 前記1つ以上のパッセンジャー化合物は、親水性、親油性、両親媒性、あるいは親水性、親油性又は両親媒性化合物の1つ以上の組み合わせである、請求項1に記載の方法。
- 前記パッセンジャー化合物は、薬剤を含む、請求項1に記載の方法。
- 前記パッセンジャー化合物は、栄養物質を含む、請求項1に記載の方法。
- 前記パッセンジャー化合物は、食品成分を含む、請求項1に記載の方法。
- 前記希釈比は、約1:10から約1:100である、請求項1に記載の方法。
- 前記方法は、前記パッセンジャー化合物の少なくとも80%の隔離率を有する、請求項1に記載の方法。
- 前記光学的に透明な保存溶液は、(a)、(b)及び(c)の各成分を一緒に混合して製造されることを特徴とする請求項1に記載の方法。
- 請求項1に記載の方法によって製造された超微細脂質構造体(USLS)。
- 請求項4に記載の方法によって製造された超微細脂質構造体(USLS)。
- 平均直径が100nm以下である、請求項18に記載の超微細脂質構造体。
- 味覚マスキングである、請求項18に記載の超微細脂質構造体。
- 保存安定性がある、請求項18に記載の超微細脂質構造体。
- 超微細脂質構造体(USLS)を生成するための光学的に透明な保存溶液であって、
(a)約0.1%〜約20%の水と約80%〜約99.9%の1種以上の水混和性有機溶媒とを含むハイドロ有機溶媒混合物と;
(b)約50mg/ml〜約250mg/mlの1種以上の脂質化合物と;
(c)1つ以上のパッセンジャー化合物と、
を含有し、
前記光学的に透明な保存溶液は、その全体に加えられた(a)、(b)及び(c)の各成分を一緒に混合することによって生成され、
水による約1:5〜約1:200の比での前記保存溶液の希釈は、請求項18のUSLSを生成する光学的に透明な保存溶液。 - 貯蔵安定性である、請求項23に記載の光学的に透明な保存溶液。
- 請求項18に記載のUSLSを含む食品。
- チョコレートである、請求項25に記載の食品。
- 請求項18に記載のUSLSを含む医薬品。
- 同じパッセンジャー化合物を有するがUSLSがない製品と比較して、1つ以上のパッセンジャー化合物の吸収及び生体内分布を変化させる、請求項27に記載の医薬品。
- 経口投与、経粘膜投与又は鼻腔内投与のために製剤化される、請求項27に記載の医薬品。
- 液体口内洗浄剤、ゲル、チューインガム、又は溶解性ストリップである、請求項18に記載のUSLSを含む口腔ケア製品。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562146465P | 2015-04-13 | 2015-04-13 | |
US62/146,465 | 2015-04-13 | ||
PCT/US2016/027194 WO2016168236A1 (en) | 2015-04-13 | 2016-04-13 | One-step method for production of ultra-small lipid structures |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2018512442A true JP2018512442A (ja) | 2018-05-17 |
Family
ID=57127009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017554519A Pending JP2018512442A (ja) | 2015-04-13 | 2016-04-13 | 超微細脂質構造体の作製のためのワンステップ法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US11298318B2 (ja) |
EP (1) | EP3283045B1 (ja) |
JP (1) | JP2018512442A (ja) |
KR (1) | KR20180016347A (ja) |
CN (1) | CN107530235B (ja) |
AU (1) | AU2016250068B2 (ja) |
CA (1) | CA2982547A1 (ja) |
DK (1) | DK3283045T3 (ja) |
IL (1) | IL255014B (ja) |
WO (1) | WO2016168236A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140271782A1 (en) | 2013-03-15 | 2014-09-18 | Dermazone Solutions, Inc. | Method for preparing nanolipids with encapsulated alcohol |
WO2020244798A1 (en) * | 2019-06-05 | 2020-12-10 | Athenion Ag | Method for taste/odor masking of a product for chronic kidney disease patients |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL64397A0 (en) | 1981-01-07 | 1982-02-28 | Weder Hans G | Process for the preparation of liposomal medicaments |
DE3585967D1 (de) * | 1984-03-08 | 1992-06-11 | Phares Pharma Holland | Liposombildende zusammensetzung. |
US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
CA1340241C (en) | 1988-06-08 | 1998-12-15 | Fountain Pharmaceuticals, Inc. | Method for marking solvent dilution microcarriers |
US5133965A (en) * | 1988-06-08 | 1992-07-28 | Fountain Pharmaceuticals, Inc. | Dressing material having adsorbed thereon a solvent dilution microcarrier precursor solution |
ES2145132T3 (es) | 1993-02-26 | 2000-07-01 | Fountain Pharm Inc | Sistema de suministro de vacunas y solucion precursora estable en almacenamiento para la encapsulacion a distancia de ingredientes activos. |
US6447800B2 (en) * | 1996-01-18 | 2002-09-10 | The University Of British Columbia | Method of loading preformed liposomes using ethanol |
WO2004002468A1 (en) * | 2002-06-26 | 2004-01-08 | Medigene Oncology Gmbh | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
DE60334618D1 (de) * | 2002-06-28 | 2010-12-02 | Protiva Biotherapeutics Inc | Verfahren und vorrichtung zur herstellung von liposomen |
CA2558255C (en) * | 2004-03-01 | 2014-01-14 | Suntory Limited | Process for producing phospholipid containing long chain polyunsaturated fatty acid as constituent thereof and utilization of the same |
US20140271782A1 (en) * | 2013-03-15 | 2014-09-18 | Dermazone Solutions, Inc. | Method for preparing nanolipids with encapsulated alcohol |
WO2008005045A2 (en) * | 2005-12-30 | 2008-01-10 | Dermazone Solutions, Inc. | Nanolipidic particles |
US20100173014A1 (en) * | 2007-05-24 | 2010-07-08 | Nanosolutions, Llc | Methods of making and using nano scale particles |
US20140335166A1 (en) * | 2013-05-08 | 2014-11-13 | Michael W. Fountain | Methods of Making and Using Nano Scale Particles |
MX2011003207A (es) * | 2008-09-27 | 2011-11-04 | Jina Pharmaceuticals Inc | Preparaciones farmaceuticas a base de lipidos para la aplicacion oral y topica; sus composiciones, metodos y usos. |
JP6038167B2 (ja) * | 2011-10-31 | 2016-12-07 | ケーン バイオテク インコーポレーテッド | 口腔疾患を予防及び治療する組成物及び方法 |
-
2016
- 2016-04-13 US US15/565,833 patent/US11298318B2/en active Active
- 2016-04-13 DK DK16780584.5T patent/DK3283045T3/da active
- 2016-04-13 CN CN201680021854.5A patent/CN107530235B/zh active Active
- 2016-04-13 JP JP2017554519A patent/JP2018512442A/ja active Pending
- 2016-04-13 AU AU2016250068A patent/AU2016250068B2/en active Active
- 2016-04-13 EP EP16780584.5A patent/EP3283045B1/en active Active
- 2016-04-13 WO PCT/US2016/027194 patent/WO2016168236A1/en active Application Filing
- 2016-04-13 KR KR1020177031553A patent/KR20180016347A/ko not_active Application Discontinuation
- 2016-04-13 CA CA2982547A patent/CA2982547A1/en active Pending
-
2017
- 2017-10-15 IL IL255014A patent/IL255014B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
US11298318B2 (en) | 2022-04-12 |
WO2016168236A1 (en) | 2016-10-20 |
CN107530235A (zh) | 2018-01-02 |
CA2982547A1 (en) | 2016-10-20 |
KR20180016347A (ko) | 2018-02-14 |
DK3283045T3 (da) | 2021-05-10 |
AU2016250068B2 (en) | 2021-04-29 |
AU2016250068A1 (en) | 2017-11-02 |
US20180110732A1 (en) | 2018-04-26 |
EP3283045A1 (en) | 2018-02-21 |
IL255014A0 (en) | 2017-12-31 |
EP3283045B1 (en) | 2021-02-17 |
EP3283045A4 (en) | 2018-11-21 |
CN107530235B (zh) | 2021-09-17 |
IL255014B (en) | 2021-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Keller | Liposomes in nutrition | |
Maherani et al. | Liposomes: a review of manufacturing techniques and targeting strategies | |
TWI759260B (zh) | 多元補充品組成物 | |
Tavano et al. | Co-encapsulation of antioxidants into niosomal carriers: gastrointestinal release studies for nutraceutical applications | |
Priprem et al. | Anxiety and cognitive effects of quercetin liposomes in rats | |
US9566237B2 (en) | Geodate delivery vehicles | |
Demirci et al. | Encapsulation by nanoliposomes | |
Saraf et al. | Advancements and avenues in nanophytomedicines for better pharmacological responses | |
FI120642B (fi) | Mikrokapseloidut liposomikoostumukset | |
AU2016250068B2 (en) | One-step method for production of Ultra-small Lipid Structures | |
US20110250239A1 (en) | Pharmaceutical and/or cosmetic composition for treating the skin | |
IL228528A (en) | Potato-based nanoparticles | |
Singh et al. | Novel approaches for dermal and transdermal delivery of herbal drugs | |
AU2016100802A4 (en) | Enhanced Trans-Dermal or Trans-Mucosal Delivery of High First-Pass Medications, Flavours and Sensations Using Terpene Micelle Nanosomes | |
Zhu et al. | Oxidation-resistant nanoliposomes loaded with osteogenic peptides: Characteristics, stability and bioaccessibility | |
Jahadi et al. | Liposomes as herbal compound carriers: An updated review | |
Anandharamakrishnan et al. | Liposomal Encapsulation in Food Science and Technology | |
Petrović et al. | Vesicular drug carriers as delivery systems | |
Imam et al. | Liposomal Carrier Systems | |
JP4942354B2 (ja) | 還元型補酵素q水溶化組成物 | |
Joshi et al. | DEVELOPMENT AND CHARACTERIZATION OF HERBOSOMES COMPLEX | |
Berry et al. | PHYTOSOMES: FROM HERBAL DRUG DELIVERY TO TARGETED CLINICAL THERAPY | |
Nair et al. | A NOVEL APPROACH FOR VESICULAR DELIVERY OF PHYTOMEDICINES USING PHYTOSOMES | |
Dwivedi et al. | Phytosomes an Emerging Technology for Herbal Drug Delivery: an Approach To Hepatoprotection | |
JP2016169167A (ja) | ポリフェノール含有リポソームおよびその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20180207 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190326 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191223 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191227 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200319 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200519 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200624 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201015 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210106 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210225 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210415 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210803 |